Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care

Despite the importance of individualised strategies for patients with type 2 diabetes mellitus (T2DM) and the availability of alternative treatments, including glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), sulphonylureas are still widely used in practice. Clinical evidence shows that GLP‐1...

Descripción completa

Detalles Bibliográficos
Autores principales: Orsini Federici, Marco, Gentilella, Raffaella, Corcos, Antonella, Torre, Enrico, Genovese, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519155/
https://www.ncbi.nlm.nih.gov/pubmed/33900667
http://dx.doi.org/10.1002/dmrr.3434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519155/
https://www.ncbi.nlm.nih.gov/pubmed/33900667
http://dx.doi.org/10.1002/dmrr.3434

Ejemplares similares